Evidence map›Paper›PMID 36798010›Full record

ArticleNeuropathology and applied neurobiology2023

A standardised protocol for blood and cerebrospinal fluid collection and processing for biomarker research in ataxia.

Magda M Santana, Laetitia S Gaspar, Maria M Pinto, Patrick Silva, Diana Adão, Dina Pereira, Joana Afonso Ribeiro, Inês Cunha, Jeannette Huebener-Schmid, Mafalda Raposo and 16 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuropathology and applied neurobiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Hereditary Ataxias in Argentina.Cerebellum (London, England) · 2025
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 13 institutions in 5 countries.

Magda M SantanaCenter for Neuroscience and Cell Biology (CNC), University of Coimbra, Coimbra, Portugal.
Laetitia S GasparCenter for Neuroscience and Cell Biology (CNC), University of Coimbra, Coimbra, Portugal.
Maria M PintoCenter for Neuroscience and Cell Biology (CNC), University of Coimbra, Coimbra, Portugal.
Patrick SilvaCenter for Neuroscience and Cell Biology (CNC), University of Coimbra, Coimbra, Portugal.
Diana AdãoCenter for Neuroscience and Cell Biology (CNC), University of Coimbra, Coimbra, Portugal.
Dina PereiraCenter for Neuroscience and Cell Biology (CNC), University of Coimbra, Coimbra, Portugal.
Joana Afonso RibeiroNeurology Department, Child Development Centre, Coimbra's Hospital and University Centre (CHUC), Coimbra, Portugal.
Inês CunhaDepartment of Neurology, Coimbra University Hospital Center (CHUC), Coimbra, Portugal.
Jeannette Huebener-SchmidInstitute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.
Mafalda RaposoInstituto de Biologia Molecular e Celular (IBMC), Instituto de Investigação e Inovação em Saúde (i3S), Universidade do Porto, Porto, Portugal.
Ana F FerreiraFaculdade de Ciências e Tecnologia (FCT), Universidade dos Açores (UAc), Ponta Delgada, Portugal.
Jennifer FaberDZNE, German Center for Neurodegenerative Diseases, Bonn, Germany.
Sandra KuhsDZNE, German Center for Neurodegenerative Diseases, Bonn, Germany.
Hector Garcia-MorenoAtaxia Centre, Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, UK.
Kathrin ReetzDepartment of Neurology, RWTH Aachen University, Aachen, Germany.
Andreas ThiemeDepartment of Neurology, Essen University Hospital, Essen, Germany.
Jon InfanteService of Neurology, University Hospital Marqués de Valdecilla (IDIVAL), University of Cantabria (UC), Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Santander, Spain.
Bart P C van de WarrenburgDepartment of Neurology, Radboud University Medical Centre, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands.
Paola GiuntiAtaxia Centre, Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, UK.
Olaf RiessInstitute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.
Ludger SchölsDepartment of Neurodegenerative Diseases and Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
Manuela LimaFaculdade de Ciências e Tecnologia (FCT), Universidade dos Açores (UAc), Ponta Delgada, Portugal.
Thomas KlockgetherDZNE, German Center for Neurodegenerative Diseases, Bonn, Germany.
Cristina JanuárioDepartment of Neurology, Coimbra University Hospital Center (CHUC), Coimbra, Portugal.
Luís Pereira de AlmeidaCenter for Neuroscience and Cell Biology (CNC), University of Coimbra, Coimbra, Portugal.
European Spinocerebellar Ataxia Type 3/Machado-Joseph Disease Initiative Study Group
University of Coimbra · PTUniversidade dos Açores · PTGerman Center for Neurodegenerative Diseases · DEUniversity of Tübingen · DECentro de Investigación Biomédica en Red · ESHertie Institute for Clinical Brain Research · DEHospitais da Universidade de Coimbra · PTJülich Aachen Research Alliance · DERadboud University Nijmegen · NLUK Dementia Research Institute · GBUniversity College London Hospitals NHS Foundation Trust · GBUniversity Hospital Bonn · DEUniversity of Duisburg-Essen · DE

Funding

Medical Research Council MR/N028767/1
6 · The paper itself

Abstract

The European Spinocerebellar Ataxia Type 3/Machado-Joseph Disease Initiative (ESMI) is a consortium established with the ambition to set up the largest European longitudinal trial-ready cohort of Spinocerebellar Ataxia Type 3/Machado-Joseph Disease (SCA3/MJD), the most common autosomal dominantly inherited ataxia worldwide. A major focus of ESMI has been the identification of SCA3/MJD biomarkers to enable future interventional studies. As biosample collection and processing variables significantly impact the outcomes of biomarkers studies, biosampling procedures standardisation was done previously to study visit initiation. Here, we describe the ESMI consensus biosampling protocol, developed within the scope of ESMI, that ultimately might be translated to other neurodegenerative disorders, particularly ataxias, being the first step to protocol harmonisation in the field.

Indexed as

Cerebellar AtaxiaMachado-Joseph DiseaseSpinocerebellar AtaxiasSpinocerebellar DegenerationsBiomarkersHumansBiomarkersataxiabiomarkersbloodcerebrospinal fluidneurodegenerative diseasesprotocolresearchstandardisation

Identifiers

PMID36798010
PMCPMC10947376
OpenAlexW4321163525

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.